This activity is intended for a broad audience of interprofessional healthcare professionals who provide care, education, and counseling for patients with obesity including primary care physicians, nurse practitioners, physician associates/physician assistants, and pharmacists.
The goal of this initiative is to increase the percentage of adults with obesity who receive guideline recommended obesity care by 15% among participating clinic sites by the conclusion of the project. This will be determined by a series of 4 quality measures. In addition, individual clinic teams participating in the project as QI teams will establish tailored process improvement goals in order to address their local gaps to improve care and patient outcomes.
Upon completion of this activity, learners should be able to:
Apply techniques to actively engage patients in the long-term management of weight loss
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Megan Adelman, PharmD, BCPS, BCGP, CDCES
Clinical Pharmacist - Family Medicine
Center for Family Medicine
Cleveland Clinic Akron General
Megan Adelman, PharmD, BCPS, BCGP, CDCES, has no relevant financial relationships to disclose.
Donna H. Ryan, MD
Pennington Biomedical Research Center
New Orleans, Louisiana
Donna Ryan, MD: advisor: Altimmune, Amgen, Biohaven, Boeringer Ingelheim, Calibrate, Carmot, Epitomee, Gila Therapeutics, Lilly, Novo Nordisk, Scientific Intake, Structure Tx, Xeno, YSOPIA, Zealand; speaker: IFA Celtic, Novo Nordisk, Lilly; individual publicly traded stock/stock options: Epitomee, Calibrate, Ro, Scientific Intake, Xeno; clinical trial: Novo Nordisk; data safety monitoring board: IQVIA (Rhythm), Lilly.
Daniel Zalinov, PA-C
Charlotte, North Carolina
Daniel Zalinov, PA-C, has no relevant financial relationships to disclose.
The planners and content peer reviewers from Clinical Care Options, LLC, ProCE, LLC, Practicing Clinicians Exchange, and Q Synthesis have no relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 05, 2023, through June 04, 2024:
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO), ProCE, LLC, Practicing Clinicians Exchange, and Q Synthesis. Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-9999-23-145-H01-P
Type of Activity: Application
Upon successfully completing the posttest with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Physician Assistant/Physician Associate Continuing Medical Education
Clinical Care Options has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until June 4, 2024. PAs should only claim credit commensurate with the extent of their participation.